Increasingly Frequent Parapneumonic Empyema by Group A Streptococcus Is More Severe Than by Streptococcus pneumoniae
- PMID: 41334964
- DOI: 10.1097/INF.0000000000005055
Increasingly Frequent Parapneumonic Empyema by Group A Streptococcus Is More Severe Than by Streptococcus pneumoniae
Abstract
Background: Streptococcus pneumoniae (Sp) is the leading bacterial pathogen causing complicated pneumonia, that is, with parapneumonic effusion/pleural empyema (PPE/PE). In 2022, there was a rise in group A Streptococcus (GAS)-complicated pneumonias in children.
Methods: We reviewed the clinical characteristics of Sp- or GAS-complicated pneumonias admitted to 4 Portuguese tertiary hospitals, in 2018-2023.
Results: Of the 128 cases, 107 were by Sp and 21 by GAS, with a rise in PPE/PE in 2023. Pathogens were identified by molecular methods (89.8%) or culture (16.4%) from pleural fluid or blood. The mean age was 3.8 years (standard deviation 2.9) and 52.3% were male. Children with GAS PPE/PE were more likely to have rash (57.1% vs. 3.8%, P < 0.001), pharyngitis (52.4% vs. 19.8%, P = 0.004), septic shock (28.6% vs. 0.9%, p<0.001), higher procalcitonin (PCT) (80 vs. 2.13 ng/mL, P = 0.005), higher rates of admission to the intensive care unit (81.0% vs. 55.1%, P = 0.030) and of invasive mechanical ventilation (38.1% vs. 11.2%, P = 0.005). Fatality rate was similar in both groups (4.8% vs. 0%, P = 0.164). Among cases where genotyping was possible, 4/7 GAS were emm1 (3/4 M1UK sublineage, all in 2023) and 64/88 Sp were serotype 3.
Conclusions: Sp serotype 3 remains the leading cause of PPE/PE in children in Portugal. The increase in GAS PPE/PE cases in 2023 followed an expansion of the M1UK sublineage in Portugal. GAS should be considered, especially in children presenting with rash, pharyngitis or higher PCT levels. Adequate antimicrobial and clinical management of GAS PPE/PE could be crucial to improve outcomes.
Keywords: pediatric pneumonia; pleural empyema.
Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The molecular study of this work was partly supported by an unrestricted research grant from Pfizer and a grant awarded by the Sociedade Portuguesa de Microbiologia Clínica e Doenças Infecciosas. The opinions expressed in this paper are those of the authors. The authors have no conflicts of interest to disclose.
References
-
- Buonsenso D, Cusenza F, Passadore L, et al. Parapneumonic empyema in children: a scoping review of the literature. Ital J Pediatr. 2024;50:136.
-
- de Benedictis FM, Kerem E, Chang AB, et al. Complicated pneumonia in children. Lancet. 2020;396:786–798.
-
- Direção-Geral de Saúde. Programa Nacional de Vacinação—Relatório anual 2024. 2025. Available at: https://www.dgs.pt/ficheiros-de-upload-2013/relatorio-pnv-2024-pdf.aspx. Accessed March 5, 2025.
-
- Johannesen TB, Munkstrup C, Edslev SM, et al. Increase in invasive group A streptococcal infections and emergence of novel, rapidly expanding sub-lineage of the virulent Streptococcus pyogenes M1 clone, Denmark, 2023. Euro Surveill. 2023;28:2300291.
-
- Gouveia C, Bajanca-Lavado MP, Mamede R, et al.; Portuguese Group for the Study of Streptococcal Infections. Sustained increase of paediatric invasive Streptococcus pyogenes infections dominated by M1UK and diverse emm12 isolates, Portugal, September 2022 to May 2023. Euro Surveill. 2023;28:2300427.
Grants and funding
LinkOut - more resources
Full Text Sources
